title: Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT.
abstract: Murine studies using anti-T-cell antibodies for conditioning in allogeneic SCT demonstrate engraftment with low rates of GVHD. On the basis of this preclinical model, we conditioned 30 patients with advanced hematologic malignancies with rabbit antithymocyte globulin (ATG) and TBI, to reduce rates of fatal acute GVHD. Patients were enrolled in two sequential groups: cohort 1 received ATG 10 mg/kg in divided doses (days -4 to -1)+200 cGy TBI (n=16), and cohort 2 received ATG (days -10 to -7)+450 cGy TBI (n=14). Median donor blood chimerism for the combined group was 94, 93 and 93% in the first, second and third months after transplant. Only three developed grade II acute GVHD despite 43% of patients receiving unrelated donor transplants. One-year survival was 71+/-11 and 54+/-14%, respectively, in recipients of related and unrelated donor SCT. Donor lymphocyte infusions were needed in 12 patients for the management of relapse and for mixed donor-recipient chimerism in 4 patients. We conclude that 10 mg/kg ATG and TBI allows engraftment with a low risk of acute GVHD; however, further dose optimization of ATG is required to achieve a balance between GVHD and disease relapse.
authors: Bone Marrow Transplant Program, Department of Internal Medicine, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA. atoor@mcvh-vcu.edu
authors: A
authors: A
authors: Toor
authors: T
authors: T
authors: Rodriguez
authors: M
authors: M
authors: Bauml
authors: H
authors: H
authors: Mathews
authors: S
authors: S
authors: Shanti
authors: D
authors: D
authors: Senitzer
authors: A
authors: A
authors: Kini
authors: J
authors: J
authors: Norton
authors: M
authors: M
authors: Parthasarathy
authors: N
authors: N
authors: Mohideen
authors: C
authors: C
authors: Petrowsky
authors: B
authors: B
authors: Bonilla
authors: S
authors: S
authors: Smith
authors: P
authors: P
authors: Stiff
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000378:metabolism; D015331:Cohort Studies; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; C512542:thymoglobulin